Selective serotonin reuptake inhibitors in older patients. A tolerability perspective.
Depression is a serious illness that is common in the elderly but which is frequently overlooked. Management is complicated by physiological changes associated with aging, the presence of comorbid physical illness, and compliance problems; these factors must be taken into account when selecting an appropriate antidepressant. The well known problems associated with the tricyclic antidepressants (TCAs) [i.e. their unwanted anticholinergic, adrenergic and histaminergic effects], which are troublesome in younger patients, can have serious consequences for elderly depressed patients. The TCAs can cause symptoms that worsen concomitant physical illness, which is frequently present in the elderly, and their cardiotoxicity in overdose is of concern in both younger and older patients. The selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors have been shown to be as efficacious as the TCAs in the general depressed population, but to lack the anticholinergic adverse effects and cardiotoxicity associated with those drugs. Their increased safety and tolerability makes them a preferred treatment for depressed elderly patients.
Skerritt
U
U
Imperial College of Science Technology, St Mary's Hospital Medical School, London, England.
Evans
R
R
Montgomery
S A
SA
D000368:Aged / Q000523:psychology*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors